A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
-
- Antonios O. Aliprantis
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Christine A. Shaw
- Moderna, Inc., Cambridge, MA, USA
-
- Paul Griffin
- QPharm, Herston, Australia
-
- Nicholas Farinola
- CMAX, Adelaide, Australia
-
- Radha A. Railkar
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Xin Cao
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Wen Liu
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Jeffrey R. Sachs
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Christine J. Swenson
- Moderna, Inc., Cambridge, MA, USA
-
- Heather Lee
- Moderna, Inc., Cambridge, MA, USA
-
- Kara S. Cox
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Daniel S. Spellman
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Colleen J. Winstead
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Igor Smolenov
- Moderna, Inc., Cambridge, MA, USA
-
- Eseng Lai
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Tal Zaks
- Moderna, Inc., Cambridge, MA, USA
-
- Amy S. Espeseth
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Lori Panther
- Moderna, Inc., Cambridge, MA, USA
収録刊行物
-
- Human Vaccines & Immunotherapeutics
-
Human Vaccines & Immunotherapeutics 17 (5), 1248-1261, 2020-10-29
Informa UK Limited
